Medtronic reports 88.1% ulcer healing rate at 24 months in VenaSeal venous leg ulcer study

• Medtronic reported new 24-month results from its VenaSeal Spectrum Venous Leg Ulcer study, presented at the 2026 VEINS conference.
• Data showed the device supported durable ulcer healing, symptom relief, quality-of-life gains, sustained vein closure, low repeat-treatment needs.
• Management framed the evidence as strengthening physician confidence in VenaSeal for advanced chronic venous disease, including active ulcers.
• U.S. commercial and Medicare coverage expanded to 96% of insured lives, lowering reimbursement friction for broader adoption.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on October 03, 2026, and is solely responsible for the information contained therein.